Summary
In response to the growing need for specialized data scientists in healthcare, our initiative aims to establish an international, interdisciplinary graduate school that educate the next generation of medical data scientists, with a strong translational focus bridging academia and industry. This is strengthened by the active involvement of leading global pharmaceutical and med-tech companies as well as SMEs in the AI field, thus ensuring that our research and training remain at the forefront of industry and healthcare. We propose a comprehensive training program offering PhD students not only a robust foundation in data science, including AI/ML and digital health, but also a deep understanding of ethical, legal and regulatory frameworks, including GDPR, the European Health Data Space and the AI Act. Our curriculum is unique in its integration of entrepreneurial thinking and a focus on Parkinson’s disease (PD) as an application field. At the same time, the methodologies and insights gained will have broader applications in various disorders, thus applicable to other areas of healthcare. We will move with our research program clearly beyond the state of the art by:
- Developing new AI/ML models spanning the entire journey of a PD patient to support medical decision-making on a more individual basis,
- Pioneering the use of recent causal AI/ML techniques in PD research,
- Investigating the optimization of future clinical trials,
- Providing novel insights into digital and neuroimaging markers,
- Developing innovative algorithmic solutions to enhance the generalizability of AI/ML models,
- Providing understanding of the ethical, legal and regulatory basis of the use of AI in medical practice.
All participants are highly committed to the research, teaching, supervision and management activities in this program, and this commitment is supported by existing working relationships through other projects, such as ERA PerMed DIGIPD, IHI PREDICTOM and IHI IDERHA.
- Developing new AI/ML models spanning the entire journey of a PD patient to support medical decision-making on a more individual basis,
- Pioneering the use of recent causal AI/ML techniques in PD research,
- Investigating the optimization of future clinical trials,
- Providing novel insights into digital and neuroimaging markers,
- Developing innovative algorithmic solutions to enhance the generalizability of AI/ML models,
- Providing understanding of the ethical, legal and regulatory basis of the use of AI in medical practice.
All participants are highly committed to the research, teaching, supervision and management activities in this program, and this commitment is supported by existing working relationships through other projects, such as ERA PerMed DIGIPD, IHI PREDICTOM and IHI IDERHA.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101168379 |
| Start date: | 01-11-2024 |
| End date: | 31-10-2028 |
| Total budget - Public funding: | - 3 722 580,00 Euro |
Cordis data
Original description
In response to the growing need for specialized data scientists in healthcare, our initiative aims to establish an international, interdisciplinary graduate school that educate the next generation of medical data scientists, with a strong translational focus bridging academia and industry. This is strengthened by the active involvement of leading global pharmaceutical and med-tech companies as well as SMEs in the AI field, thus ensuring that our research and training remain at the forefront of industry and healthcare. We propose a comprehensive training program offering PhD students not only a robust foundation in data science, including AI/ML and digital health, but also a deep understanding of ethical, legal and regulatory frameworks, including GDPR, the European Health Data Space and the AI Act. Our curriculum is unique in its integration of entrepreneurial thinking and a focus on Parkinson’s disease (PD) as an application field. At the same time, the methodologies and insights gained will have broader applications in various disorders, thus applicable to other areas of healthcare. We will move with our research program clearly beyond the state of the art by:- Developing new AI/ML models spanning the entire journey of a PD patient to support medical decision-making on a more individual basis,
- Pioneering the use of recent causal AI/ML techniques in PD research,
- Investigating the optimization of future clinical trials,
- Providing novel insights into digital and neuroimaging markers,
- Developing innovative algorithmic solutions to enhance the generalizability of AI/ML models,
- Providing understanding of the ethical, legal and regulatory basis of the use of AI in medical practice.
All participants are highly committed to the research, teaching, supervision and management activities in this program, and this commitment is supported by existing working relationships through other projects, such as ERA PerMed DIGIPD, IHI PREDICTOM and IHI IDERHA.
Status
SIGNEDCall topic
HORIZON-MSCA-2023-DN-01-01Update Date
25-11-2024
Images
No images available.
Geographical location(s)
Search
Organisations
-
| FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (Coördinator)
-
| CENTRE HOSPITALIER DE LUXEMBOURG
-
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
-
| GE HEALTHCARE GMBH
-
| INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE
-
| KI ELEMENTS GMBH
-
| LUXEMBOURG INSTITUTE OF HEALTH
-
| NOVO NORDISK A/S
-
| PETANUX GMBH
-
| RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN
-
| ROYAL COLLEGE OF SURGEONS IN IRELAND
-
| UNIVERSIDAD DE NAVARRA
-
| UNIVERSITA DI PISA
-
| UNIVERSITE DE NAMUR ASBL (UNamur)
-
| UNIVERSITE DU LUXEMBOURG